197 related articles for article (PubMed ID: 32861832)
1. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.
Dent M; Hamorsky K; Vausselin T; Dubuisson J; Miyata Y; Morikawa Y; Matoba N
Cell Mol Gastroenterol Hepatol; 2021; 11(1):185-198. PubMed ID: 32861832
[TBL] [Abstract][Full Text] [Related]
2. Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope.
Hamorsky KT; Kouokam JC; Dent MW; Grooms TN; Husk AS; Hume SD; Rogers KA; Villinger F; Morris MK; Hanson CV; Matoba N
Mol Ther; 2019 Nov; 27(11):2038-2052. PubMed ID: 31471224
[TBL] [Abstract][Full Text] [Related]
3. Impact of glycoengineering and antidrug antibodies on the anticancer activity of a plant-made lectin-Fc fusion protein.
Dent M; Mayer KL; Verjan Garcia N; Guo H; Kajiura H; Fujiyama K; Matoba N
Plant Biotechnol J; 2022 Nov; 20(11):2217-2230. PubMed ID: 35900183
[TBL] [Abstract][Full Text] [Related]
4. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
[TBL] [Abstract][Full Text] [Related]
5. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a lectibody targeting cancer-associated high-mannose glycans.
Oh YJ; Dent MW; Freels AR; Zhou Q; Lebrilla CB; Merchant ML; Matoba N
Mol Ther; 2022 Apr; 30(4):1523-1535. PubMed ID: 35077861
[TBL] [Abstract][Full Text] [Related]
7. Griffithsin has antiviral activity against hepatitis C virus.
Meuleman P; Albecka A; Belouzard S; Vercauteren K; Verhoye L; Wychowski C; Leroux-Roels G; Palmer KE; Dubuisson J
Antimicrob Agents Chemother; 2011 Nov; 55(11):5159-67. PubMed ID: 21896910
[TBL] [Abstract][Full Text] [Related]
8. A novel anti-HIV-1 bispecific bNAb-lectin fusion protein engineered in a plant-based transient expression system.
Seber Kasinger LE; Dent MW; Mahajan G; Hamorsky KT; Matoba N
Plant Biotechnol J; 2019 Aug; 17(8):1646-1656. PubMed ID: 30729651
[TBL] [Abstract][Full Text] [Related]
9. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
[TBL] [Abstract][Full Text] [Related]
10. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF
Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416
[TBL] [Abstract][Full Text] [Related]
11. Role of N-linked glycans in the interactions of recombinant HCV envelope glycoproteins with cellular receptors.
Chen PC; Chuang PK; Chen CH; Chan YT; Chen JR; Lin SW; Ma C; Hsu TL; Wong CH
ACS Chem Biol; 2014 Jul; 9(7):1437-43. PubMed ID: 24766301
[TBL] [Abstract][Full Text] [Related]
12. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
13. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of hepatitis B and C virus envelope glycoproteins.
Jeulin H; Velay A; Murray J; Schvoerer E
World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
[TBL] [Abstract][Full Text] [Related]
15. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.
Helle F; Wychowski C; Vu-Dac N; Gustafson KR; Voisset C; Dubuisson J
J Biol Chem; 2006 Sep; 281(35):25177-83. PubMed ID: 16809348
[TBL] [Abstract][Full Text] [Related]
16. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
[TBL] [Abstract][Full Text] [Related]
17. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.
Feld JJ; Cypel M; Kumar D; Dahari H; Pinto Ribeiro RV; Marks N; Kamkar N; Bahinskaya I; Onofrio FQ; Zahoor MA; Cerrochi O; Tinckam K; Kim SJ; Schiff J; Reichman TW; McDonald M; Alba C; Waddell TK; Sapisochin G; Selzner M; Keshavjee S; Janssen HLA; Hansen BE; Singer LG; Humar A
Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):649-657. PubMed ID: 32389183
[TBL] [Abstract][Full Text] [Related]
18. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
20. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
